ClinicalTrials.gg
CompletedNCT05844735Updated Sep 16, 2025

A Randomized Placebo- and Active Comparator-controlled Study to Evaluate the Photosafety of SAR441566

A Phase 1 interventional study of SAR441566 and Placebo in Rheumatoid Arthritis, sponsored by Sanofi. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-16.

Sponsored by Sanofi · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2023, 3 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies in Arthritis, Rheumatoid by Sanofi — 2 open to participants now, 2 under way, none of them phase 3. Arthritis, Rheumatoid · Sanofi.

Enrollment
26th of 34
60 · median 108
Started
2023
with 2 others
Phase 1
9 of 36
1 open now
Registered
30th of 36
by date

Among the 36 studies in Arthritis, Rheumatoid by Sanofi, this one is the 26th largest by enrollment of the 34 interventional ones that give a count, is one of 3 that started in 2023, is one of 9 in phase 1, and was the 30th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

2 of the 36 studies in Arthritis, Rheumatoid by Sanofi are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Arthritis, Rheumatoid by Sanofi, or all of them as a file.
02

Study summary

This is a single center randomized parallel-group partially-blinded, 4-arm Phase 1 study to evaluate the phototoxic potential of two dose levels of SAR441566 treatment compared to placebo and the active comparator, ciprofloxacin, in healthy adults, 18 to 55 years of age.

There will be two parts:

  • Part I is a randomized placebo-controlled trial comparing sensitivity to ultraviolet (UV) light in participants treated with SAR441566 to those treated with placebo.
  • Part II is an open label arm consisting of participants treated with ciprofloxacin which induces mild phototoxicity and serves as a positive control.
Read the detailed description

The overall duration of the study for each participant will be up to approximately 48 days

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants who are between 18 and 55 years of age, (inclusive), at the time of signing the
  • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and .
  • Participants with Fitzpatrick skin type classification of I, II, or III (I always burns easily, never tans, II always burns easily, tans minimally, III Burns moderately, tans gradually)
  • Body weight within 50.0 and 100.0 kg (inclusive), and (BMI) within the range 18.0 and 32.0 kg/m2 (inclusive)

Exclusion criteria

Exclusion Criteria:

  • A positive (HBsAg, anti-HBc), or test at screening, indicative of a current or past infection
  • A history of active tuberculosis (TB) or positive serological test for TB (Quantiferon TB Gold or T-SPOT)
  • History of invasive opportunistic infections
  • Participants with a history of Clostridium difficile-associated diarrhea
  • Participants with a history of occurring within 5 years before inclusion (except adequately treated carcinoma in situ of the cervix, or adequately treated non- squamous cell or basal cell carcinoma of the skin)
  • Active skin disorders or alterations such as tattoos on the back where photosensitivity testing will be performed or unprotected ultraviolet exposure of the test areas within 4 weeks prior to baseline photo testing that the Investigator considers will interfere with study assessments
  • Abnormal skin response during preliminary or baseline phototoxicity evaluations
  • Any medication within 14 days before inclusion or within 5 times the elimination half-life or pharmacodynamic half-life of the medication (whichever is longer); any acetaminophen intake within 2 days prior the inclusion and any biologics (antibody or its derivatives) given within 4 months before screening
  • Any participant enrolled or having participated, in this or any other clinical study involving an IMP or in any other type of medical research within the past 14 days (last day of IMP dosing in the previous clinical trial) or 5 half-lives whichever is longer, before screening
  • Clinical signs and symptoms consistent with COVID-19 or laboratory-confirmed SARS-CoV-2 infection; SARS-CoV-2 infection within 4 weeks prior to screening; and/or history of severe course of COVID-19
  • If female, pregnancy (defined as positive beta-HCG blood test and/or positive urine pregnancy test), breast-feeding

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Part I SAR441566 Dose A

    Participants will receive repeated low dose of SAR441566 for 7.5 days

    Drug: SAR441566

  • Experimental
    Part I SAR441566 Dose B

    Participants will receive repeated high dose of SAR441566 for 7.5 days

    Drug: SAR441566

  • Placebo comparator
    Part I Placebo

    Participants will receive repeated SAR441566 matching placebo tablets for 7.5 days

    Drug: Placebo

  • Active comparator
    Part II Ciprofloxacin

    Participants will receive repeated ciprofloxacin 500 mg twice-daily (BID) for 5.5 days

    Drug: Ciprofloxacin

Interventions

06

What researchers measure

Primary outcomes

  1. Treatment part I: Photosensitivity Index (PI) at 10 minutes post UV irradiation under Condition 1

    The PI is calculated as the ratio of the minimal erythema dose (MEDbaseline) measured on Day -2 at 10 minutes post-irradiation to the corresponding MEDon-drug measured on Day 8 at 10 minutes post-irradiation. Condition 1 is Full range solar ultraviolet B/ultraviolet A (UVB/UVA) \[290 to 400 nm\] exposure.

    Time frame: On-drug Day 8

  2. Treatment part I: Photosensitivity Index (PI) at 1 hour post UV irradiation under Condition 1

    The PI is calculated as the ratio of the minimal erythema dose (MEDbaseline) measured on Day -2 at 1 hour post-irradiation to the corresponding MEDon-drug measured on Day 8 at 1 hour post-irradiation. Condition 1 is full range solar UVB/UVA \[290 to 400 nm\] exposure.

    Time frame: On-drug Day 8

  3. Treatment part I: Photosensitivity Index (PI) at 24 hours post UV irradiation under Condition 1

    The PI is calculated as the ratio of the minimal erythema dose (MEDbaseline) measured on Day -1 at 24 hours post-irradiation to the corresponding MEDon-drug measured on Day 9 at 24 hours post-irradiation. Condition 1 is a Full range solar UVB/UVA \[290 to 400 nm\] exposure.

    Time frame: On-drug Day 9

  4. Treatment part I: Photosensitivity Index (PI) at 10 minutes post UV irradiation under Condition 2

    The PI is calculated as the ratio of the minimal erythema dose (MEDbaseline) measured on Day -2 at 10 minutes post-irradiation to the corresponding MEDon-drug measured on Day 8 at 10 minutes post-irradiation. Condition 2 is a UVA only \[320 to 400 nm\] exposure.

    Time frame: On-drug Day 8

  5. Treatment part I: Photosensitivity Index (PI) at 1 hour post UV irradiation under Condition 2

    The PI is calculated as the ratio of the minimal erythema dose (MEDbaseline) measured on Day -2 at 1 hour post-irradiation to the corresponding MEDon-drug measured on Day 8 at 1 hour post-irradiation. Condition 2 is a UVA only \[320 to 400 nm\] exposure.

    Time frame: On-drug Day 8

  6. Treatment part I: Photosensitivity Index (PI) at 24 hours post UV irradiation under Condition 2

    The PI is calculated as the ratio of the minimal erythema dose (MEDbaseline) measured on Day -1 at 24 hours post-irradiation to the corresponding MEDon-drug measured on Day 9 at 24 hours post-irradiation. Condition 2 is a UVA only \[320 to 400 nm\] exposure.

    Time frame: On-drug Day 9

Secondary outcomes

  1. Treatment part I & part II: Minimum Erythema Dose (MED) percent change from baseline at 10 minutes, 1 hour, and 24 hours postirradiation measured under Condition 1 and Condition 2

    Condition 1 is full range solar UVB/UVA \[290 to 400 nm\] exposure and condition 2 is a UVA only \[320 to 400 nm\] exposure.

    Time frame: Baseline (Day -2 to Day -1) and on-drug (Day 8 to Day 9)

  2. Treatment part I & part II: Evaluation of local skin reactions following exposure to UV irradiation at 10 minutes, 1 hour, 24 hours, 48 hours, and 72 hours postirradiation under Condition 1, Condition 2, and Condition 3

    Condition 1 is full range solar UVB/UVA \[290 to 400 nm\] exposure, condition 2 is a UVA only \[320 to 400 nm\] exposure and condition 3 is a full solar range UVB/UVA + UVA \[16 J/cm2\] exposure.

    Time frame: At Baseline (Day -2 to Day 1 pre-dose) and on-drug (Day 8 to Day 11)

  3. Treatment part I: Assessment of Plasma pharmacokinetic parameter of SAR441566: Cmax

    Maximum plasma concentration observed

    Time frame: Day 8 to Day 11

  4. Treatment part I: Assessment of Plasma pharmacokinetic parameter of SAR441566: Tmax,

    Time to reach Cmax

    Time frame: Day 8 to Day 11

  5. Treatment part I: Assessment of Plasma pharmacokinetic parameter of SAR441566: AUC0-tau

    Area under the plasma concentration versus time curve calculated using the trapezoidal method over the dosing interval (0 to 24 hours)

    Time frame: Day 8 to Day 9

  6. Treatment part I: Number of participants with adverse events (AE) and treatment-emergent adverse events (TEAEs)

    Assessment of adverse events (AE) / treatment-emergent adverse events (TEAE) including serious adverse event (SAE) and adverse event of special interests (AESI)

    Time frame: Up to Day 20

  7. Treatment part II: Photosensitivity Index (PI) at 10 minutes post UV irradiation under Condition 1

    Condition 1 is full range solar UVB/UVA \[290 to 400 nm\] exposure.

    Time frame: On-drug Day 8

  8. Treatment part II: Photosensitivity Index (PI) at 1 hour post UV irradiation under Condition 1

    Condition 1 is full range solar UVB/UVA \[290 to 400 nm\] exposure.

    Time frame: On-drug Day 8

  9. Treatment part II: Photosensitivity Index (PI) at 24 hours post UV irradiation under Condition 1

    Condition 1 is full range solar UVB/UVA \[290 to 400 nm\] exposure.

    Time frame: On-drug Day 9

  10. Treatment part II: Photosensitivity Index (PI) at 10 minutes Condition 2

    Condition 2 is a UVA only \[320 to 400 nm\] exposure.

    Time frame: On-drug Day 8

  11. Treatment part II: Photosensitivity Index (PI) at 1 hour post UV irradiation under Condition 2

    Condition 2 is a UVA only \[320 to 400 nm\] exposure.

    Time frame: On-drug Day 8

  12. Treatment part II: Photosensitivity Index (PI) at 24 hours post UV irradiation under Condition 2

    Condition 2 is a UVA only \[320 to 400 nm\] exposure.

    Time frame: On-drug Day 9

07

Study locations

1 site
  • TKL Research, Inc. Site Number : 8400001
    Fair Lawn, New Jersey 07410, United States
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized, and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Oct 2023, 4 months.

Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's 4 months is below that.

Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2023
First posted
May 6, 2023
StartActual
May 22, 2023
Primary completionActual
Oct 15, 2023
CompletionActual
Oct 23, 2023
Last update
Sep 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05844735
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
May 6, 2023
Start date
May 22, 2023
Primary completion
Oct 15, 2023
Completion
Oct 23, 2023
Last update
Sep 16, 2025

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Balinatunfib

Start the discussion